Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Down 11.4% in August

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 14,000,000 shares, a decline of 11.4% from the July 31st total of 15,800,000 shares. Approximately 9.0% of the company’s stock are short sold. Based on an average trading volume of 2,340,000 shares, the days-to-cover ratio is currently 6.0 days.

Insider Activity at Ironwood Pharmaceuticals

In related news, Director Catherine Moukheibir sold 44,426 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the completion of the sale, the director now directly owns 84,207 shares in the company, valued at $535,556.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the completion of the sale, the director now directly owns 84,207 shares of the company’s stock, valued at $535,556.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Minardo John sold 9,910 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the sale, the insider now directly owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The disclosure for this sale can be found here. Insiders sold 77,102 shares of company stock worth $468,063 over the last three months. 12.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of IRWD. Vanguard Group Inc. grew its stake in shares of Ironwood Pharmaceuticals by 21.8% during the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after purchasing an additional 3,487,821 shares during the period. Pacer Advisors Inc. grew its stake in shares of Ironwood Pharmaceuticals by 23.6% during the 2nd quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock worth $58,078,000 after purchasing an additional 1,701,452 shares during the period. Renaissance Technologies LLC grew its stake in shares of Ironwood Pharmaceuticals by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock worth $55,889,000 after purchasing an additional 1,472,097 shares during the period. Armistice Capital LLC grew its stake in shares of Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock worth $50,856,000 after purchasing an additional 2,400,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Ironwood Pharmaceuticals by 40.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock worth $36,892,000 after purchasing an additional 1,226,377 shares during the period.

Wall Street Analyst Weigh In

IRWD has been the subject of several research analyst reports. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Finally, Wells Fargo & Company decreased their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD traded down $0.05 during midday trading on Friday, hitting $5.06. The company’s stock had a trading volume of 1,325,731 shares, compared to its average volume of 2,489,212. Ironwood Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $15.70. The firm’s 50 day moving average is $5.89 and its 200-day moving average is $7.55.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.